Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for enhancing the potency of the immune checkpoint inhibitors

a technology potent immune response, which is applied in the field can solve the problems of patients who cannot mount a potent immune response to fully eliminate cancer cells, significant proportion of responders experience tumor relapse, and high liver toxicity of patients with braf-mutated melanoma. achieve the effect of enhancing the potency of immune checkpoint inhibitors

Active Publication Date: 2020-11-03
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about using a combination of a substance called SK1 and an immune checkpoint inhibitor to treat melanoma or other cancers. The researchers found that when SK1 was knocked down in melanoma, it increased the activity and proliferation of CD8+ T cells, which are important for fighting cancer. This combination also led to a more powerful immune response against melanoma compared to using only the immune checkpoint inhibitor alone. The patent suggests that targeting both melanoma and the immune system may be necessary to effectively treat cancer. The combination of the two substances was also found to enhance the potency of the immune checkpoint inhibitor, which is currently being tested in cancer treatments.

Problems solved by technology

However, tumors can escape host immunity by manipulating the tumor microenvironment and driving immunosuppression, meaning that patients cannot mount a potent enough immune response to fully eliminate cancer cells.
Despite promising results, about 40% of patients do not display therapeutic response and a significant proportion of responders experience tumor relapse in the 2 years following treatment induction.
Moreover, recent clinical trials combining BRAF and checkpoint inhibitors have shown high liver toxicity for patients with BRAF-mutated melanoma.
However, the prior art does not suggest SK1 inhibition could enhance the potency of the immune checkpoint inhibitors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for enhancing the potency of the immune checkpoint inhibitors
  • Methods for enhancing the potency of the immune checkpoint inhibitors
  • Methods for enhancing the potency of the immune checkpoint inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example

[0061]Material & Methods

[0062]Cell Culture

[0063]Yumm murine melanoma cells, which harbor BRAFV600E mutation, Pten and Cdkn2a deletion [1] were kindly provided by Dr. S. Tartare-Deckert (INSERM U1065 Nice, France). Yumm cells were grown as monolayers in OptiMEM media supplemented with 3% heat-inactivated fetal calf serum (FCS) in the presence of 5% CO2 in a humidified atmosphere at 37° C. To guarantee cell line authenticity, Yumm cell lines were used for a limited number of passages and routinely tested for the expression of melanocyte-lineage proteins such as MelanA / MART1. MC38 cells were kindly provided by Drs T. Chardes et A. Pélegrin (INSERM U1194, Montpellier, France) and were cultured in DMEM containing 10% FCS, 2 mM glutamine, 0.1 mM non essential amino acids, 1 mM sodium pyruvate and 10 mM Hepes.

[0064]Cell Transfection

[0065]Yumm cells were co-transfected, in a 1:10 ratio, with the pEGFP-N empty vector and a SK1 shRNA (shSK1 or shSK1(2)) plasmid (shRNA from Thermoscientific) o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
plasma dehydrogenaseaaaaaaaaaa
reduction of functionaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.

Description

FIELD OF THE INVENTION[0001]The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors.BACKGROUND OF THE INVENTION[0002]The ability of the immune system to detect and eliminate cancer was first proposed over 100 years ago. Since then, T cells reactive against tumor-associated antigens have been detected in the blood of patients with many different types of cancers, suggesting a role for the immune system in fighting cancer. However, tumors can escape host immunity by manipulating the tumor microenvironment and driving immunosuppression, meaning that patients cannot mount a potent enough immune response to fully eliminate cancer cells. The goal of immunotherapy is to restore or augment antitumor immune responses. An increased understanding of tumor immunology has led to the identification of novel targets for new immune-based approaches, including a group of cell-surface molecules known as immune checkpoint proteins. In particular, monoclon...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K39/00A61K31/133C07K16/28A61K31/137A61K31/40A61K31/415A61K31/4245A61K31/426A61K31/4535A61K45/06A61K39/395G01N33/569A61P35/00G01N33/574
CPCA61K31/4245A61K45/06A61K31/426A61P35/00G01N33/574A61K31/40A61K31/133A61K39/3955A61K31/415C07K16/2818A61K31/137G01N33/56972A61K31/4535A61K2300/00G01N2333/70517A61K2039/505A61K2039/507G01N2800/52
Inventor LEVADE, THIERRYMEYER, NICOLASCOLACIOS VIATGÉ, CÉLINEIMBERT, CAROLINEANDRIEU-ABADIE, NATHALIESEGUI, BRUNO
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com